JP2023537051A5 - - Google Patents

Info

Publication number
JP2023537051A5
JP2023537051A5 JP2023508466A JP2023508466A JP2023537051A5 JP 2023537051 A5 JP2023537051 A5 JP 2023537051A5 JP 2023508466 A JP2023508466 A JP 2023508466A JP 2023508466 A JP2023508466 A JP 2023508466A JP 2023537051 A5 JP2023537051 A5 JP 2023537051A5
Authority
JP
Japan
Prior art keywords
heavy chain
light chain
antibody
pharmaceutically acceptable
solvate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023508466A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023537051A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CN2021/112462 external-priority patent/WO2022033578A1/zh
Publication of JP2023537051A publication Critical patent/JP2023537051A/ja
Publication of JP2023537051A5 publication Critical patent/JP2023537051A5/ja
Pending legal-status Critical Current

Links

JP2023508466A 2020-08-13 2021-08-13 抗体薬物複合体 Pending JP2023537051A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN202010814877.X 2020-08-13
CN202010814877 2020-08-13
PCT/CN2021/112462 WO2022033578A1 (zh) 2020-08-13 2021-08-13 抗体药物偶联物

Publications (2)

Publication Number Publication Date
JP2023537051A JP2023537051A (ja) 2023-08-30
JP2023537051A5 true JP2023537051A5 (cg-RX-API-DMAC7.html) 2024-08-21

Family

ID=80247729

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023508466A Pending JP2023537051A (ja) 2020-08-13 2021-08-13 抗体薬物複合体

Country Status (14)

Country Link
US (2) US12622977B2 (cg-RX-API-DMAC7.html)
EP (2) EP4768463A2 (cg-RX-API-DMAC7.html)
JP (1) JP2023537051A (cg-RX-API-DMAC7.html)
KR (1) KR20230051214A (cg-RX-API-DMAC7.html)
CN (8) CN119792562A (cg-RX-API-DMAC7.html)
AU (1) AU2021323863A1 (cg-RX-API-DMAC7.html)
BR (1) BR112023002417A2 (cg-RX-API-DMAC7.html)
CA (1) CA3188508A1 (cg-RX-API-DMAC7.html)
DK (1) DK4183421T3 (cg-RX-API-DMAC7.html)
FI (1) FI4183421T3 (cg-RX-API-DMAC7.html)
IL (1) IL300446A (cg-RX-API-DMAC7.html)
MX (1) MX2023001648A (cg-RX-API-DMAC7.html)
PT (1) PT4183421T (cg-RX-API-DMAC7.html)
WO (1) WO2022033578A1 (cg-RX-API-DMAC7.html)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112022022036A2 (pt) * 2020-04-30 2022-12-13 Chia Tai Tianqing Pharmaceutical Group Co Ltd Construtos de ligação ao antígeno que têm como alvo her2 e usos dos mesmos
EP4768463A2 (en) 2020-08-13 2026-07-01 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Antibody drug conjugate
CA3224492A1 (en) 2021-07-19 2023-01-26 Xiaojun Han Immunoconjugates and methods
US11806405B1 (en) 2021-07-19 2023-11-07 Zeno Management, Inc. Immunoconjugates and methods
IL311324A (en) 2021-09-16 2024-05-01 Chia Tai Tianqing Pharmaceutical Group Co Ltd A drug-antibody conjugate against HER3, a preparation including it and its use
EP4562051A1 (en) * 2022-07-26 2025-06-04 Immunome, Inc. Immunoconjugates and methods
EP4623936A1 (en) * 2022-11-22 2025-10-01 Keymed Biosciences (Chengdu) Co., Ltd. Fused ring compound, conjugate thereof and use thereof
CN119300868B (zh) * 2023-05-11 2026-03-13 映恩生物科技(上海)有限公司 喜树碱类化合物及其偶联物、其制备方法和用途
CN120958033B (zh) * 2023-08-04 2026-03-31 映恩生物制药(苏州)有限公司 抗体药物偶联物的识别抗体及其应用
CN122161619A (zh) 2023-10-25 2026-06-05 正大天晴药业集团南京顺欣制药有限公司 抗her2抗体药物偶联物治疗乳腺癌的用途
CN117257977A (zh) * 2023-11-07 2023-12-22 正大天晴药业集团南京顺欣制药有限公司 用于制备抗体药物偶联物的方法
CN122295133A (zh) 2023-12-22 2026-06-26 正大天晴药业集团股份有限公司 靶向her2的adc治疗乳腺癌的用途
WO2025155943A1 (en) * 2024-01-18 2025-07-24 Joinn Biologics Us Inc. Immunoconjugates comprising camptothecin analogs and methods of use thereof
WO2025162211A1 (zh) * 2024-01-29 2025-08-07 正大天晴药业集团股份有限公司 抗her2抗体药物偶联物治疗胃癌的用途
WO2025162287A1 (zh) 2024-01-29 2025-08-07 正大天晴药业集团股份有限公司 抗her2抗体药物偶联物治疗肠癌的用途
WO2025186213A1 (en) 2024-03-04 2025-09-12 Debiopharm International S.A. Combination of a wee1 inhibitor and a topoisomerase 1 inhibitor
WO2025242061A1 (zh) * 2024-05-21 2025-11-27 正大天晴药业集团股份有限公司 抗her2抗体药物偶联物治疗胆道癌的用途
WO2025252039A1 (zh) * 2024-06-03 2025-12-11 正大天晴药业集团股份有限公司 抗her2抗体药物偶联物治疗非小细胞肺癌的用途
KR20250175725A (ko) * 2024-06-07 2025-12-17 (주)지아이이노베이션 Cd80 단백질 및 il-2 단백질을 포함하는 융합단백질 및 항체-약물 접합체를 포함하는 암 치료용 약학 조성물
CN118702819B (zh) * 2024-07-03 2025-10-03 武汉华美生物工程有限公司 一种抗dxd及其衍生物的抗体及其制备和应用
WO2026015407A1 (en) * 2024-07-10 2026-01-15 Asieris Pharmaceuticals (Usa), Inc. Linkers for conjugates and methods of use thereof
WO2026086844A1 (zh) * 2024-10-23 2026-04-30 正大天晴药业集团股份有限公司 靶向EGFR和c-Met的抗体药物偶联物
CN121570606A (zh) * 2024-10-23 2026-02-27 正大天晴药业集团股份有限公司 靶向EGFR和c-Met的抗体药物偶联物
WO2026114362A1 (zh) * 2024-11-29 2026-06-04 正大天晴药业集团股份有限公司 抗体-偶联物、其制备方法及应用
WO2026124488A1 (zh) * 2024-12-10 2026-06-18 正大天晴药业集团股份有限公司 抗her2抗体药物偶联物或其联用药物治疗非小细胞肺癌的用途
WO2026158430A1 (zh) * 2025-01-23 2026-07-30 正大天晴药业集团股份有限公司 靶向her2的adc治疗妇科肿瘤的用途
CN121466318A (zh) * 2026-01-07 2026-02-06 哈尔滨医科大学 基于生物正交反应的抗体偶联药物及其制备方法与应用

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5945311A (en) 1994-06-03 1999-08-31 GSF--Forschungszentrumfur Umweltund Gesundheit Method for producing heterologous bi-specific antibodies
AR024464A1 (es) 1999-06-25 2002-10-02 Genentech Inc Anticuerpos anti-erbb2 humanizados.
JP2005522514A (ja) 2002-04-10 2005-07-28 ジェネンテック・インコーポレーテッド 抗her2抗体改変体
DE10355904A1 (de) * 2003-11-29 2005-06-30 Merck Patent Gmbh Feste Formen von anti-EGFR-Antikörpern
KR101505157B1 (ko) 2012-05-08 2015-03-24 주식회사 종근당 항―ErbB2 항체 변이체
US10195288B2 (en) 2012-10-11 2019-02-05 Daiichi Sankyo Company, Limited Antibody-drug conjugate
CN103319599B (zh) 2013-05-27 2015-02-18 上海交联药物研发有限公司 一种抗人ErbB2抗体—美登木素偶联物及其应用
WO2015054659A1 (en) 2013-10-11 2015-04-16 Mersana Therapeutics, Inc. Protein-polymer-drug conjugates
EP3068892A4 (en) 2013-11-13 2017-05-31 Zymeworks Inc. Monovalent antigen binding constructs targeting egfr and/or her2 and uses thereof
LT3074424T (lt) * 2013-11-27 2025-05-26 Zymeworks Bc Inc. Bispecifiniai antigeną surišantys konstruktai, nukreipti į her2
JP6510532B2 (ja) 2013-12-20 2019-05-08 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト 二重特異性her2抗体及び使用方法
SG11201603960XA (en) * 2014-01-31 2016-07-28 Daiichi Sankyo Co Ltd Anti-her2 antibody-drug conjugate
WO2016077505A2 (en) * 2014-11-11 2016-05-19 Amunix Operating Inc. Targeted xten conjugate compositions and methods of making same
CN104610453A (zh) * 2015-01-23 2015-05-13 张帆 一类抗her2双靶向抗体、其制备方法及用途
CN107446045A (zh) 2016-07-22 2017-12-08 北京天广实生物技术股份有限公司 一种抗her2的抗体、其药物组合物及用途
SG11201908784TA (en) 2017-03-27 2019-10-30 Hoffmann La Roche Improved antigen binding receptor formats
CN109106951A (zh) * 2017-08-18 2019-01-01 四川百利药业有限责任公司 一种喜树碱-抗体偶联物
UA130338C2 (uk) 2018-09-26 2026-01-28 Джянгсу Хенгруй Медісін Ко., Лтд. Кон'югат ліганд-лікарський засіб аналога ексатекану, спосіб його отримання та його застосування
JP7408646B2 (ja) 2018-09-30 2024-01-05 ジエンス ハンソー ファーマスーティカル グループ カンパニー リミテッド 抗-b7h3抗体-エキサテカンアナログコンジュゲート及びその医薬用途
US20220143178A1 (en) 2019-02-03 2022-05-12 Shanghai Bao Pharmaceuticals Co., Ltd. Anti-her2 bispecific antibody and application thereof
EP4768463A2 (en) 2020-08-13 2026-07-01 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Antibody drug conjugate

Similar Documents

Publication Publication Date Title
KR102236259B1 (ko) 항-lag-3 항체 및 그것의 사용
US20230405141A1 (en) Antibody drug conjugate
HRP20201144T1 (hr) Protutijela anti-cd3 i postupci uporabe
JP2022506072A5 (cg-RX-API-DMAC7.html)
JP2020510422A5 (cg-RX-API-DMAC7.html)
CN116199785A (zh) 多特异性抗体及其制备和使用方法
JP2017534253A5 (cg-RX-API-DMAC7.html)
JP2021515793A5 (cg-RX-API-DMAC7.html)
FI3765525T3 (fi) Biparatooppisen her2-vasta-aineen ja lääkkeen konjugaatteja ja käyttömenetelmiä
CN113121639B (zh) 澳瑞他汀类似物及其偶联物、其制备方法及其应用
US20240382607A1 (en) Drug conjugate of eribulin derivative
JP2022502079A5 (cg-RX-API-DMAC7.html)
JP2025524306A (ja) Itga2を標的とする抗体及びそれを含む抗体薬物複合体
AU2018285523A1 (en) Antibody drug conjugates that bind LGR5
WO2022262772A1 (en) Anti-her3 antibody, antibody drug conjugate containing the same, and use thereof
JP2024536383A5 (cg-RX-API-DMAC7.html)
WO2024230755A1 (zh) 一种抗pdl1抗体-药物偶联物及应用
WO2024212922A1 (zh) 喜树碱类化合物及其偶联物、其制备方法和用途
JP2024538755A5 (cg-RX-API-DMAC7.html)
JP2024540536A5 (cg-RX-API-DMAC7.html)
TW202302595A (zh) 依喜替康類似物的結晶形式及其製備方法
JP2024523438A5 (cg-RX-API-DMAC7.html)
RU2025111318A (ru) АНТИ-αvβ6 АНТИТЕЛА И КОНЪЮГАТЫ АНТИТЕЛО-ЛЕКАРСТВЕННОЕ СРЕДСТВО И ИХ ПРИМЕНЕНИЕ В ЛЕЧЕНИИ РАКА
WO2025257185A1 (en) Humanized anti-human-carcinoembryonic antigen antibody
WO2026067491A1 (zh) 抗体或者抗体药物偶联物与其他治疗剂的组合的应用